Identifying prospective clinical trial candidates

Learn what clinical trial participation involves and whether it aligns with your needs, goals, and circumstances.

Our approach to safety in psychedelic therapy

Discover how our comprehensive care model protects both physical and psychological well-being.

Safety, agency, and recovery: trauma-informed care at Sunstone

Continuous informed consent, psychological safety, and individualized care are built into every step of the treatment process.

Advancing standards in MDMA psychedelic therapy research training

We are setting the industry standard for high quality training for mental health professionals in psychedelic therapy research.

Meet Dr. Manish Agrawal – Psychedelic Oncology Leader

Manish Agrawal, MD, brings an extensive academic, clinical, and research background and depth of experience to Sunstone.

How psychedelic-assisted therapy may complement ongoing mental health care

As psychedelic-assisted therapies continue advancing through clinical research, understanding how they fit within existing mental health care systems is increasingly important.

How psychedelic treatment could transform veteran care

Why veterans’ trauma requires new therapeutic approaches.

Research explores how psilocybin-assisted group therapy addresses existential distress in cancer patients

New findings that deepen understanding of how psilocybin-assisted group therapy can help people with cancer and depression.

Sunstone’s 2Dose Study: Advancing psilocybin-assisted therapy in cancer care

This clinical trial will explore whether psilocybin is more effective than an active placebo and if two doses are better than one.

Research Highlights Meaning-Centered Psychotherapy as Promising Partner for Psilocybin Therapy in Cancer Care

A new paper published in Psychedelic Medicine introduces a novel model combining Meaning-Centered Psychotherapy (MCP) with psilocybin-assisted therapy (PAT) for patients with advanced cancer and depression. Developed from Sunstone Therapies’ investigator-initiated trial, the approach—called MCP-PSIL—aims to help patients reduce distress and find deeper meaning while navigating serious illness.

View All

Psilocybin‐assisted group therapy in patients diagnosed with cancer and depression

Agrawal M., Richards W., Beaussant Y., et al. “Psilocybin‐assisted group therapy in patients with cancer diagnosed with a major depressive disorder.” Cancer, July 2023.

Direct observation measure of therapeutic connection in psilocybin-assisted therapy

Gramling R., Bennett E., Curtis K., et al. “Developing a Direct Observation Measure of Therapeutic Connection in Psilocybin-Assisted Therapy: A Feasibility Study.” Journal of Palliative Medicine, August 2023.

Group psychedelic therapy: empirical estimates of cost-savings and improved access

Marseille E., Stauffer C., Agrawal M., et al. “Group psychedelic therapy: empirical estimates of cost-savings and improved access.” Front. Psychiatry, Dec. 2023.

Acceptability of psilocybin-assisted group therapy in patients with cancer and MDD

Beaussant Y., Tarbi E., Nigam K., et al. “Acceptability of psilocybin-assisted group therapy in patients with cancer and MDD.” Cancer, Dec 2023.

The potential for psychedelics to treat Prolonged Grief Disorder

Ehrenkranz R., Agrawal M., Penberthy J., Yaden., D. "Narrative review of the potential for psychedelics to treat Prolonged Grief Disorder." International Review of Psychiatry, May 2024.

View All